Garry Nicholson and Dr. Gabriela Gruia resigned from TScan Therapeutics' Board of Directors, effective October 13, 2026. The company stated that neither resignation resulted from any disagreement regarding operations or policies. In connection with these departures, the Board appointed Stephen Biggar as a member and R. Keith Woods as chairperson of the Nominating and Corporate Governance Committee. TScan Therapeutics operates in the biotechnology industry, focusing on developing immunotherapies for cancer treatment.
